Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

PRI-724 is a prodrug form of the β-catenin/CREB-binding protein (CBP) inhibitor C-82 and a derivative of ICG-001 (Item No. 16257).1 It is cytotoxic to GES-1 gastric mucosal and HGC-27, MKN45, and AGS gastric cancer cells (IC50s = 16.53, 9.8, 44.28, and 3.48 µM, respectively) and enhances decreases in viability induced by lonidamine (Item No. 14640) or 2-deoxy-D-glucose (2-DG; Item No. 14325) in CAL 27, SCC-25, and BICR 22 tongue squamous carcinoma cells.2,3 PRI-724 (0.4 mg/animal) reduces hepatic fibrosis in a mouse model of liver fibrosis induced by carbon tetrachloride (CCl4).1 It reduces the proliferation of CD4+ or CD8+ stem cell memory and central memory T cells in a rhesus macaque model of antiretroviral therapy-suppressed simian immunodeficiency virus (SIV) infection when administered at doses of 10 or 20 mg/kg per day.4
WARNING This product is not for human or veterinary use.
1. Inhibition of cyclic adenosine monophosphate (cAMP)-
2. A novel UBE2T inhibitor suppresses Wnt/β-
3. The Wnt signaling pathway inhibitors improve the therapeutic activity of glycolysis modulators against tongue cancer cells. Int. J. Mol. Sci. 23(3), 1248 (2022).
4. Pharmacological modulation of the Wnt/β-